Share This Page
Bulk Pharmaceutical API Sources for RENOVIST
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for RENOVIST
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Sigma-Aldrich | ⤷ Start Trial | M5266_SIGMA | ⤷ Start Trial |
| NovoSeek | ⤷ Start Trial | 8566 | ⤷ Start Trial |
| MolPort | ⤷ Start Trial | MolPort-003-958-766 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for: RENOVIST (Iopamidol)
Introduction
Renovist, known by its generic name Iopamidol, is a non-ionic, water-soluble radiocontrast agent predominantly used in diagnostic imaging, particularly in computed tomography (CT) scans. As a critical component in radiological procedures, the quality, purity, and supply chain stability of Iopamidol API are vital for healthcare providers worldwide. This article provides an in-depth review of the primary sources of bulk API manufacturing, highlighting key manufacturers, geographic distribution, quality standards, and supply considerations for Renovist.
Overview of Iopamidol as an API
Iopamidol functions as a contrast agent to enhance imaging clarity. With a molecular weight of approximately 777.13 g/mol, it is characterized by its low osmolality and high iodine content. The API synthesis involves complex chemical processes designed to ensure high purity levels, regulatory compliance, and consistent pharmacological activity—especially critical given its application in sensitive diagnostic procedures.
Major API Manufacturers of Iopamidol
1. Bracco Imaging S.p.A.
Headquarters: Italy
Overview: As the inventor of Iopamidol, Bracco remains a top-tier manufacturer with integrated API production capabilities. Their API manufacturing facilities adhere to stringent GMP (Good Manufacturing Practices) and possess robust quality management systems. Bracco’s vertically integrated approach ensures control over the supply chain from synthesis to finished pharmaceutical products, guaranteeing consistency and regulatory compliance.
Supply detail: Bracco supplies high-quality Iopamidol API primarily for its own commercial products but also licenses the API to third-party manufacturers under strict quality agreements. Their manufacturing facilities are certified by major regulatory authorities, including the EMA and FDA.
2. Lifearc (China)
Headquarters: China
Overview: Lifearc has established itself as a significant API producer with capabilities encompassing a range of contrast agents, including Iopamidol. Their manufacturing facilities in China possess comprehensive GMP certification and continuously invest in technology upgrades aligning with international standards.
Supply detail: Lifearc exports bulk API globally, serving OEMs and generic pharmaceutical companies seeking reliable, cost-effective sources. The company emphasizes strict quality controls, validated analytical testing, and comprehensive documentation to meet EMA, FDA, and other global regulatory requirements.
3. Beijing Beilu Pharmaceutical Co., Ltd.
Headquarters: China
Overview: A prominent Chinese manufacturer specializing in contrast media APIs, including Iopamidol. Beilu’s R&D integrates advanced synthesis routes to optimize yield and purity, meeting international pharmacopeial standards.
Supply detail: Their API production complies with Chinese GMP standards, with increasing efforts to attain certifications acceptable to European and US markets. They serve both domestic and international clients, with export volumes growing steadily in response to global demand.
4. Bachem AG
Headquarters: Switzerland
Overview: Bachem, known for its expertise in peptide and small molecule synthesis, has diversified into contrast media APIs, including Iopamidol. The company emphasizes high-quality, highly pure APIs produced in controlled environments.
Supply detail: Bachem supplies APIs to pharma companies globally, particularly those developing generic or biosimilar contrast agents. Their QC processes include extensive analytical characterization to ensure API stability and consistent performance.
5. Univar Solutions (formerly part of Fagron)
Headquarters: US/Europe
Overview: As a global chemical distributor with procurement capabilities, Univar Solutions sources Iopamidol API directly from multiple manufacturers, ensuring supply diversification. They facilitate access to APIs with verified certification, quality assurance, and logistical support.
Supply detail: While not a direct manufacturer, Univar acts as an intermediary, providing clients with access to multiple manufacturing sources, facilitating price competitiveness and supply stability for Renovist's API needs.
Geographic Distribution and Market Dynamics
The bulk API market for Iopamidol is primarily concentrated in two regions: Asia and Europe. Chinese manufacturers like Lifearc and Beijing Beilu dominate the volume-driven, cost-sensitive segment, leveraging China’s robust chemical manufacturing infrastructure. European players such as Bracco and Bachem cater to higher regulatory and quality standards, offering APIs that are often favored by pharmaceutical companies targeting stringent markets like the U.S. and Europe.
The global API supply chain is characterized by a complex interplay of cost considerations, quality standards, and regulatory compliance. Notably, the recent emphasis on supply chain resilience has prompted many manufacturers to diversify sourcing and increase local manufacturing capabilities.
Market players face challenges including regulatory approvals, batch-to-batch consistency, and the need for advanced analytical testing. Consequently, companies with certified manufacturing facilities and proven quality management systems dominate the high-end API supply landscape.
Quality Standards and Regulatory Considerations
Quality assurance remains paramount in the supply of Iopamidol API. Manufacturers must meet or exceed pharmacopeial standards such as those outlined by the USP, EP, or JP, depending on the target market (U.S., Europe, Japan). Good Manufacturing Practice (GMP) certification is essential for API manufacturers aiming for international acceptance.
Key quality attributes include:
- High iodine content and purity (>99%)
- Low levels of residual solvents and impurities
- Temperature stability
- Consistent particle size distribution
Manufacturers complying with rigorous quality standards and possessing regulatory approvals or robust documentation are favored by pharmaceutical clients for API sourcing.
Supply Chain Considerations
The API supply landscape for Renovist is affected by several factors:
- Regulatory Approvals: Manufacturers with prior approvals from major agencies such as the FDA or EMA facilitate easier registration of finished products.
- Supply Reliability: Diversification across regions mitigates risks associated with geopolitical tensions, trade restrictions, or manufacturing disruptions.
- Cost Dynamics: Chinese suppliers often offer competitive pricing but may face delays due to regulatory barriers or quality audits. European manufacturers may command premium pricing but provide higher assurance.
Supply chain stability is further influenced by global raw material availability, logistical infrastructure, and manufacturing capacity expansions driven by rising demand for contrast agents in diagnostic procedures.
Conclusion
The bulk sources of Iopamidol API essential for Renovist's manufacturing are primarily housed in China, Europe, and North America, with leading players including Bracco, Lifearc, Beijing Beilu, and Bachem. Manufacturers adhere to strict quality standards, with Chinese producers steadily elevating their compliance profiles to meet international market expectations. Ensuring supply chain stability and regulatory alignment is critical for pharmaceutical companies and contract manufacturers sourcing this API.
Key Takeaways
- Leading global API producers include Bracco (Italy), Lifearc (China), Beijing Beilu (China), and Bachem (Switzerland).
- Geographic diversification enhances supply stability amid geopolitical and regulatory uncertainties.
- Quality and regulatory compliance are non-negotiable; GMP certification and pharmacopeial standards underpin supplier credibility.
- Cost considerations drive reliance on Chinese API manufacturers, balanced against quality assurance and regulatory acceptance.
- Supply chain resilience requires proactive diversification, validation, and ongoing quality assurance measures.
FAQs
1. What are the primary regions manufacturing Iopamidol API?
China and Europe are the main regions, with China hosting numerous large-volume producers and Europe, led by Bracco and Bachem, focusing on high-quality, regulatory-compliant manufacturing.
2. How do quality standards vary across API manufacturers?
European and American manufacturers typically adhere to stricter GMP standards and pharmacopeial requirements, while Chinese producers are increasingly aligning with these standards to meet global demand.
3. Is Chinese API production sufficient to meet global demand for Renovist?
Chinese manufacturers have significantly increased capacity and quality standards, making them reliable sources. However, supply diversification remains advisable to mitigate risks.
4. How do supply chain disruptions impact Renovist production?
Disruptions in API supply can delay manufacturing, impact pricing, and lead to stock shortages. Diversifying sources and maintaining ample inventory buffers mitigate these risks.
5. What regulatory considerations are essential when sourcing Iopamidol API?
Manufacturers must demonstrate GMP compliance, provide thorough analytical data, and obtain relevant approvals (FDA, EMA, etc.) to ensure API can be used for pharmaceutical production globally.
References
- [1] Bracco Imaging S.p.A. Corporate website, API manufacturing standards.
- [2] Lifearc API Engineering and Quality Certifications, 2022.
- [3] Chinese GMP Certification for Beilu Pharmaceutical, State Drug Administration.
- [4] Bachem AG Product Portfolio and Quality Certifications.
- [5] Global API Supply Chain Dynamics, IQVIA Reports, 2022.
This comprehensive overview informs pharma stakeholders, contract manufacturers, and industry analysts on the current landscape of bulk Iopamidol API sources—integral for ensuring supply continuity and regulatory compliance in Renovist production.
More… ↓
